


LYRGABA

Pregabalin 75 mg, 150 mg capsules

TREATMENT OF NEUROPATHIC PAIN



Copyright © : shutterstock.com



Avalon Pharma

TRUSTED HEALTHCARE SOLUTIONS

LYRGABA

Pregabalin 75 mg, 150 mg capsules

TREATMENT OF NEUROPATHIC PAIN



LYRGABA (pregabalin)

- ◆ **LYRGABA** (pregabalin) provides significant reduction in pain, sleep disturbance and anxiety in cases of DPN, PHN & spinal cord injury¹
- ◆ **LYRGABA** (pregabalin) provides rapid reduction of pain and anxiety as early as week 1 in cases of DPN, PHN & Spinal cord injury²
- ◆ **LYRGABA** (pregabalin) is SFDA approved in treatment of DPN, PHN & Spinal cord injury³

LYRGABA
Pregabalin 75 mg, 150 mg capsules

- 1. What LYRGABA is and what it is used for:**
Neuropathic pain: Lyrgaba is indicated for the treatment of peripheral and central neuropathic pain in adults.
- 2. Before you take LYRGABA:**
Don't use Lyrgaba: if you have a history of allergic (hypersensitive) to pregabalin or any of the other ingredients of Lyrgaba capsule.
Pregnancy and lactation: Lyrgaba should not be used during pregnancy unless clearly necessary (if the benefit to breast-feeding is not recommended during treatment with pregabalin).
Effects on ability to drive and use machines: Lyrgaba may have minor or moderate influence on the ability to drive and use machines. Lyrgaba may cause dizziness and somnolence and therefore may influence the ability to drive or use machines.
- 3. How to take LYRGABA:**
The usual dose is: The dose range is 150 to 600 mg per day given in either two or three divided doses, Lyrgaba may be taken with or without food.
Discontinuation of pregabalin: In accordance with current clinical practice, if pregabalin has to be discontinued it is recommended this should be done gradually over a minimum of 1 week independent of the indication.
No dose adjustment is required for patients with hepatic impairment.
- 4. Possible side effects:**
The most commonly reported adverse reactions were dizziness and somnolence. In all controlled studies, the discontinuation rate due to adverse reactions was 12% for patients receiving pregabalin and 5% for patients receiving placebo. The most common adverse reactions resulting in discontinuation from pregabalin treatment groups were dizziness and somnolence.
- 5. How to store Lyrgaba:**
 - Keep this medicine out of the sight and reach of children.
 - Do not use Lyrgaba after the expiry date which is stated on the carton and on the tube after EXP. The expiry date refers to the last day of that month.
 - This medicinal product does not require any special storage conditions.
 - Store below 30°C.



1. Summary of products characteristics, SPC/revised on 12/2014. Available upon request.
2. Joseph C Arezzo, Julio Rosenstock, Linda LaMoreaux and Lynne Pauer, BMC Neurology 2008, 8:33 doi:10.1186/1471-2377-8-33.
3. Siddall, MBBS, PhD; M.J. Cousins, MD, DSc; A. Otte, MD, PhD; T. Griesing, PhD; R. Chambers, MSPH; and T.K. Murphy, PhD, NEUROLOGY 2006;67:1792-1800.

 **Avalon Pharma**

Middle East Pharmaceutical Industries Co. Ltd.
P.O. Box 301332 Riyadh 11372
Tel: +966 11 464 3924
Fax: +966 11 462 0471
Email: info@avalon.com.sa avalonpharmaceutical.com